Cellectar Biosciences Inc
CLRB
NASDAQ
Biotechnology
$2.60
USD
+0.12 (+4.84%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $19.82M
Volume 46.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-22.32M
TTM
+23.2%
YoY
Operating Cash Flow
$-19.47M
TTM
+43.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 3.6 | 2.3 | 2.5 | 2.8 | 2.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 6.0 | 4.9 | 5.7 | 5.8 | 7.2 |
Operating Income | -6.0 | -4.9 | -5.7 | -5.8 | -7.2 |
EBITDA | -6.0 | -4.8 | -5.6 | -5.9 | -7.2 |
Other Income / Expense | 0.5 | 0.3 | 0.3 | 0.1 | 0.1 |
Total Other Income / Expense | 0.6 | 0.4 | 0.4 | 0.1 | 0.3 |
Income Before Income Taxes | -5.4 | -4.4 | -5.3 | -5.7 | -6.9 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -5.4 | -4.4 | -5.3 | -5.7 | -6.9 |
Consolidated Net Income / Loss | -5.4 | -4.4 | -5.3 | -5.7 | -6.9 |
Net Income Attributable to Common Shareholders | -5.4 | -4.4 | -5.3 | -5.7 | -6.9 |
Basic EPS | -$3.39 | -$1.41 | -$1.28 | -$1.33 | -$0.57 |
Diluted EPS | -$3.39 | -$1.41 | -$1.28 | -$1.33 | -$0.57 |
Basic Shares Outstanding | 1.6M | 3.2M | 4.1M | 4.2M | 12.2M |
Diluted Shares Outstanding | 1.6M | 3.2M | 4.1M | 4.2M | 12.2M |